Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05663957 · ClinicalTrials.gov registry record
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
A clinical trial of SARS-CoV-2, COVID-19, sponsored by AstraZeneca.
- Completed
- Registry status
- 5,814
- Enrollment target
- 1
- Study location
NCT05663957 is a study of SARS-CoV-2, COVID-19 that has completed, run by AstraZeneca. The registered enrollment target is 5,814 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05663957, a study of SARS-CoV-2, COVID-19, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 5,814 participants
- Enrollment target
- 1
- Study location
Study Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the Department of Veterans Affairs (VA) Health System.
Conditions Studied
Interventions
- DRUG Evusheld
Study Locations (1)
Utah
- Research Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,814 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2023-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05663957
The ClinicalTrials.gov registry entry for NCT05663957 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,814 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2, COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Evusheld is the first listed.
NCT05663957 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05663957 about?
NCT05663957 is a clinical study titled "eVusheld Assessment reaL wORld Effectiveness in the VA Health System". An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient popu...
What is the current status of trial NCT05663957?
This trial is currently completed. The enrollment target is 5,814 participants. The study started on 2023-01-04. Estimated completion is 2023-09-01.
What conditions does trial NCT05663957 study?
This clinical trial studies the following conditions: SARS-CoV-2, COVID-19.
What interventions are being tested in trial NCT05663957?
The interventions under investigation include: Evusheld (DRUG).
Who is sponsoring clinical trial NCT05663957?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05663957 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.